---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-037501"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:13:53.206110+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review

## Summary
- 83% of target accounts have added or are actively progressing LYMPHIR through formulary review.
- Market access covering ~80% of covered lives via ~135 health plans; no reimbursement denials reported.
- Initial accounts placing repeat orders; sequential growth in orders since launch.
- Investigator-led studies: LYMPHIR prior to CAR-T in DLBCL (U Minnesota) and combo with pembrolizumab in solid tumors (UPMC).
- Field team onboarding underway; international expansion with distribution agreements in Europe/Middle East.

## SEC filing metadata
- accession: 0001213900-26-037501
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/0001213900-26-037501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/ea0284321-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-037501
- JSON: https://secwatch.observer/filing/0001213900-26-037501.json
- Plain text: https://secwatch.observer/filing/0001213900-26-037501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.